Hims & Hers launches generic semaglutide offering in Canada

Semaglutide just got a boost in Canada: Hims & Hers has rolled out a generic version of this peptide for the Canadian market. This is a big move for researchers, especially anyone following the rapid growth of semaglutide research worldwide. Until now, most semaglutide access in Canada meant brand-name products, limited supply, or cross-border headaches.

Now, researchers in Canada can source generic semaglutide more efficiently. This isn’t just about convenience. It means more labs and clinicians can participate in semaglutide research, potentially at a lower cost.

Key points:

Why does this matter? Semaglutide has been one of the hottest research peptides for metabolic studies, with ongoing work on its impact on appetite, blood sugar, and weight regulation. Broader access to high-purity, generic semaglutide could mean more real-world data, more robust protocols, and maybe even some unexpected findings.

For anyone sourcing research peptides in Canada, this is a clear signal that the market is expanding. Researchers have more choice — and more leverage — than ever before. Check out our semaglutide page for a technical overview, or browse the vendor directory if you’re comparing sources.

Canada’s peptide research community just got a new tool. Watch this space.